Funding for this research was provided by:
National Cancer Institute (P30CA008748)
Received: 15 May 2019
Accepted: 26 November 2019
First Online: 2 January 2020
: D.Z. reports consulting fees from Merck, Synlogic Therapeutics, Tizona Therapeutics, and Tesaro, outside the submitted work. D.Z. has a patent for use of Newcastle Disease Virus for cancer therapy, outside the submitted work. J.S. Reis-Filho reports personal/consultancy fees from VolitionRx, Page.AI, Invicro, Roche, Genentech, Ventana, Goldman Sachs and REPARE Therapeutics, outside the submitted work. The remaining authors declare no competing interests.